Clinical trial
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage…
NCT00032045 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00032045 |
|---|---|
| Title | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma |
| Official title | An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100 antigen, incomplete Freund's adjuvant, ipilimumab |
| Start date | Jan 1, 2002 |
| Completion | Aug 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: